Catalent, Inc. (NYSE:CTLT) Short Interest Update

Catalent, Inc. (NYSE:CTLT) was the target of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 8,630,000 shares, a growth of 25.6% from the May 31st total of 6,870,000 shares. Based on an average trading volume of 1,660,000 shares, the days-to-cover ratio is currently 5.2 days.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Stephens restated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. Barclays boosted their target price on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday. Finally, StockNews.com started coverage on Catalent in a research note on Sunday. They issued a “sell” rating on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Catalent currently has an average rating of “Hold” and a consensus price target of $55.65.

Insider Activity at Catalent

In other Catalent news, insider Ricky Hopson sold 1,401 shares of the stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total transaction of $76,018.26. Following the completion of the transaction, the insider now directly owns 20,617 shares of the company’s stock, valued at approximately $1,118,678.42. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Catalent

A number of institutional investors have recently added to or reduced their stakes in the business. Lindbrook Capital LLC lifted its position in shares of Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after buying an additional 208 shares during the last quarter. Czech National Bank lifted its position in shares of Catalent by 0.7% during the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after purchasing an additional 228 shares during the last quarter. BNP Paribas Asset Management Holding S.A. boosted its stake in Catalent by 1.9% during the 4th quarter. BNP Paribas Asset Management Holding S.A. now owns 17,850 shares of the company’s stock valued at $802,000 after purchasing an additional 328 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its holdings in Catalent by 6.2% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,703 shares of the company’s stock valued at $256,000 after buying an additional 331 shares during the last quarter. Finally, Arizona State Retirement System increased its position in Catalent by 0.7% in the 4th quarter. Arizona State Retirement System now owns 49,546 shares of the company’s stock worth $2,226,000 after buying an additional 365 shares during the period.

Catalent Trading Down 0.1 %

Shares of NYSE:CTLT opened at $56.17 on Tuesday. Catalent has a 12-month low of $31.80 and a 12-month high of $60.20. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. The firm has a fifty day moving average of $55.56 and a two-hundred day moving average of $54.06.

Catalent (NYSE:CTLT) last issued its earnings results on Wednesday, May 8th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). The firm had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.11 billion. Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. Equities analysts predict that Catalent will post -0.17 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.